BICEPS Beyond neuroInflammation: new Concepts to Elucidate the immune system’s vital role in Parkinson’s disease
- Coordinator
- Rijksuniversiteit Groningen, Netherlands
- Runs
- 1 November 2024 to 31 October 2028
- Status
- Running
- EU funding
- €3.9m
- Total cost
- —
- Partners
- 17 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101167843
What the project is doing
In the project's own words, from its summary on CORDIS.
Decades of research into Parkinson's disease (PD) have fallen short in fully comprehending its mechanisms, leaving us without a cure. Current treatments merely alleviate symptoms temporarily, but are unable to impede the progression of the disease. Clearly, PD research has hit a wall, and new approaches are needed. Recent discoveries of the involvement of the peripheral immune system in PD have sparked a groundbreaking proposition by BICEPS: PD must be considered a systemic disease with an immune response involving both brain and periphery.
Thus, to revolutionize PD research, we must shift away from the neuro-centric approach of past decades and extend our focus to studying the immune system outside the brain. Furthermore, recent advancements, such as systems biology and artificial intelligence (AI)-driven data mining, diagnosis, and drug development, hold significant promise for advancing PD research. Therefore, BICEPS is uniting PD researchers, immunologists, and experts in AI and systems biology from leading European academic institutions, startup companies, and established pharmaceutical firms into a unique consortium.
The primary objective is to train a new generation of PD researchers with interdisciplinary expertise in these fields. This ambitious goal will be realized through an intensive training program that encompasses cutting-edge methodologies, encourages innovation, nurtures transferable skills, and provides immersive, hands-on research experiences. Thereby, the BICEPS network aims to shape the future of PD research by adopting a fresh perspective and expediting the development of diagnostics and therapies for PD, with a particular focus on the immune system.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Rijksuniversiteit Groningen | Groningen | Netherlands | Coordinator |
| Association Europeenne Pour La Maladie De Parkinson | Bruxelles / Brussel | Belgium | Associatedpartner |
| Bayer Aktiengesellschaft | Leverkusen | Germany | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Deutsches Zentrum Fur Neurodegenerative Erkrankungen eV | Bonn | Germany | Associatedpartner |
| Deutsches Zentrum Fur Neurodegenerative Erkrankungen eV | Bonn | Germany | Participant |
| Freie Universitaet Berlin | Berlin | Germany | Associatedpartner |
| Metasysx GmbH | Potsdam | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| H. Lundbeck AS | Valby | Denmark | Participant |
| Anacalypsis Therapeutics Idiotiki Kefalaiouchiki Etaireia | Moschato | Greece | Participant |
| Ethniko Kai Kapodistriako Panepistimio Athinon | Athina | Greece | Participant |
| Sulfateq B.v. | Groningen | Netherlands | Participant |
| Faculty of Medicine, University of Belgrade | Belgrade | Serbia | Participant |
| Suleyman Demirel University | Isparta | Türkiye | Associatedpartner |
| Semikal Teknoloji Sanayi ve Tic. Ltd. Sti. | Isparta | Türkiye | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI